Glenmark Pharmaceuticals is planning to acquire a front-end pharmaceutical company for about Rs. 100 crores to mark its foray in the European market. The target company is in Central Europe with a strong marketing force and some approved products and the deal is likely to be through before the end of March. The name of the company has not been disclosed. As of now, Glenmark just has an office in the UK for business development.
Read The Economic Times article.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment